Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Ascierto · SciRah

Researcher profile · Semantic Scholar

P. Ascierto

Share profile

P. Ascierto — researcher profile on SciRah

h-index: 116
Works: 1,159
Citations: 86K

Most-cited papers

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
C. Blank, M. Lucas, R. Scolyer, B. A. van de Wiel +64 more
2024New England Journal of Medicine448 citations Open access
Semantic Scholar
Systemic Therapy for Melanoma: ASCO Guideline Update
Rahul Seth, S. Agarwala, H. Messersmith, K. Alluri +26 more
2023Journal of Clinical Oncology206 citations Open access
Semantic Scholar
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
J. Larkin, M. Del Vecchio, M. Mandalà, H. Gogas +27 more
2023Clinical Cancer Research171 citations Open access
Semantic Scholar
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
N. Núñez, F. Berner, Ekaterina Friebel, S. Unger +38 more
2023i Medicina126 citations Open access
Semantic Scholar
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
A. Eggermont, M. Kicinski, C. Blank, Mario Mandalá +26 more
2024European Journal of Cancer100 citations Open access
Semantic Scholar
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
P. Ascierto, M. Casula, J. Bulgarelli, M. Pisano +33 more
2024Nature Communications95 citations Open access
Semantic Scholar
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
A. Diab, H. Gogas, S. Sandhu, G. Long +22 more
2023Journal of Clinical Oncology79 citations Open access
Semantic Scholar
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
D. Schadendorf, R. Dummer, K. T. Flaherty, C. Robert +16 more
2024European Journal of Cancer78 citations Open access
Semantic Scholar
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
R. Dummer, P. Queirolo, Pauline Gerard Duhard, Youyou Hu +11 more
2023The Lancet Oncology70 citations
Semantic Scholar
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer.
A. Cortellini, A. D'Alessio, S. Cleary, S. Buti +54 more
2023Clinical Cancer Research70 citations Open access
Semantic Scholar
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop
G. Clifton, M. Rothenberg, P. Ascierto, G. Begley +13 more
2023Journal for ImmunoTherapy of Cancer42 citations Open access
Semantic Scholar
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
C. Garbe, R. Dummer, T. Amaral, R. Amaria +22 more
2023Nature Medicine39 citations Open access
Semantic Scholar
Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors.
P. Bossi, P. Ascierto, N. Basset-Seguin, B. Dréno +13 more
2023Critical reviews in oncology/hematology37 citations Open access
Semantic Scholar
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
Georgina V. Long, F. Hodi, E. J. Lipson, D. Schadendorf +16 more
2023NEJM Evidence36 citations
Semantic Scholar
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
D. Mallardo, M. Fordellone, Andrew White, M. Ottaviano +14 more
2023Journal of Translational Medicine36 citations Open access
Semantic Scholar
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
O. Hamid, J. Hassel, A. Shoushtari, F. Meier +12 more
2023Journal for ImmunoTherapy of Cancer31 citations Open access
Semantic Scholar
Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer
B. Mlecnik, A. Lugli, G. Bindea, F. Marliot +87 more
2023Cancers31 citations Open access
Semantic Scholar
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Mario Mandalá, P. Lorigan, M. C. Sergi, N. Benannoune +25 more
2024European Journal of Cancer28 citations Open access
Semantic Scholar
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases.
A. Hauschild, J. Hassel, M. Ziemer, P. Rutkowski +16 more
2024Journal of Clinical Oncology26 citations
Semantic Scholar
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai, A. Shaheen, Charlotte Grieco, Paolo D. d’Arienzo +42 more
2024EClinicalMedicine25 citations Open access
Semantic Scholar
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
S. Jacques, Janet McKeown, P. Grover, Douglas B. Johnson +35 more
2024European Journal of Cancer24 citations
Semantic Scholar
Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)
G. Long, M. Del Vecchio, J. Weber, C. Hoeller +16 more
2023SKIN The Journal of Cutaneous Medicine24 citations Open access
Semantic Scholar
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
F. Janku, Tae Min Kim, G. Iyer, A. Spreafico +18 more
2023European Journal of Cancer23 citations Open access
Semantic Scholar
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study).
Mario Mandalá, A. Ferrari, I. Brecht, K. Suijkerbuijk +26 more
2024European Journal of Cancer21 citations Open access
Semantic Scholar
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
R. Dummer, P. Corrie, R. Gutzmer, T. Meniawy +22 more
2023Journal of Clinical Oncology21 citations Open access
Semantic Scholar
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.
A. Weppler, L. Da Meda, I. Pires da Silva, Wen Xu +12 more
2023European Journal of Cancer21 citations
Semantic Scholar
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
M. Atkins, P. Ascierto, D. Feltquate, J. Gulley +7 more
2023Journal for ImmunoTherapy of Cancer21 citations Open access
Semantic Scholar
Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
Amedeo A. Azizi, D. Hargrave, João Passos, P. Wolkenstein +6 more
2024Neuro-Oncology Practice20 citations Open access
Semantic Scholar
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
O. Kennedy, M. Kicinski, S. Valpione, S. Gandini +26 more
2023European Journal of Cancer20 citations Open access
Semantic Scholar
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
P. Ascierto, R. Dummer, H. Gogas, A. Arance +13 more
2023Journal of Clinical Oncology20 citations Open access
Semantic Scholar
Methylation-sensitive restriction enzyme-droplet digital PCR assay for the one-step highly sensitive analysis of DNA methylation hotspots
Giuseppe Gattuso, Alessandro Lavoro, R. Caltabiano, G. Madonna +5 more
2024International Journal of Molecular Medicine19 citations Open access
Semantic Scholar
NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.
P. Ascierto, P. Bossi, M. Mandalà, P. Queirolo +12 more
2023Journal of Clinical Oncology18 citations
Semantic Scholar
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
P. Ascierto, Mario Mandalá, P. F. Ferrucci, M. Guidoboni +33 more
2024NEJM Evidence17 citations Open access
Semantic Scholar
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
C. Ertl, T. Ruf, Dirk Mentzer, M. Kong +31 more
2023European Journal of Cancer16 citations
Semantic Scholar
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
J. Luke, P. Ascierto, M. Khattak, L. de la Cruz Merino +16 more
2023Journal of Clinical Oncology16 citations
Semantic Scholar
Health Economic Consequences Associated With COVID-19–Related Delay in Melanoma Diagnosis in Europe
L. V. Maul, Dagmar Jamiolkowski, Rebecca Lapides, A. Mueller +22 more
2024JAMA Network Open15 citations Open access
Semantic Scholar
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
H. Tawbi, F. Hodi, E. Lipson, D. Schadendorf +15 more
2023Journal of Clinical Oncology15 citations
Semantic Scholar
Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness
M. Mannino, A. Piccerillo, G. Fabbrocini, P. Quaglino +14 more
2023Dermatology15 citations Open access
Semantic Scholar
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
C. Trojaniello, F. Sparano, E. Cioli, P. Ascierto
2023Current Oncology Reports15 citations Open access
Semantic Scholar
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
Khalil Choucair, C. Nebhan, A. Cortellini, Stijn Hentzen +22 more
2023Cancers14 citations Open access
Semantic Scholar
Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin
Vittorio Castaldo, M. Minopoli, F. di Modugno, A. Sacconi +16 more
2023Journal of experimental & clinical cancer research : CR14 citations Open access
Semantic Scholar
Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma
D. Mallardo, F. Sparano, M. G. Vitale, C. Trojaniello +13 more
2024Cancer Immunology and Immunotherapy13 citations Open access
Semantic Scholar
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
R. Dummer, K. Flaherty, C. Robert, A. Arance +14 more
2023Future Oncology13 citations Open access
Semantic Scholar
Common Toxicities associated with Immune Checkpoint Inhibitors and Targeted Therapy in the Treatment of Melanoma: A Systematic Scoping Review.
M. Egeler, M. van Leeuwen, I. Fraterman, N. M. J. van den Heuvel +9 more
2023Critical reviews in oncology/hematology12 citations Open access
Semantic Scholar
Long-Term Outcomes and Persistent Toxicities Following BRAF/MEK Inhibitor Therapy for Advanced Melanoma
Rachel S. Goodman, L. Di Guardo, A. Maurichi, Brendan Kirwin +19 more
2023European Journal of Cancer12 citations Open access
Semantic Scholar
Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
D. Galati, S. Zanotta, M. Capone, G. Madonna +10 more
2023Journal of Translational Medicine12 citations Open access
Semantic Scholar
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
A. M. Taylor, Janet McKeown, F. Dimitriou, S. Jacques +25 more
2024European Journal of Cancer11 citations
Semantic Scholar
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
L. Cantini, F. Paoloni, Federica Pecci, F. Spagnolo +47 more
2023Journal of the National Cancer Institute10 citations Open access
Semantic Scholar
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
D. Schadendorf, J. Luke, P. Ascierto, Georgina V. Long +16 more
2024Journal for ImmunoTherapy of Cancer9 citations Open access
Semantic Scholar
New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer
S. Costantini, G. Madonna, E. Di Gennaro, F. Capone +11 more
2023International Journal of Molecular Sciences9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Arance×9
Invite
A. Arance — researcher profile on SciRah
A. Menzies×8
Invite
A. Menzies — researcher profile on SciRah
M. Carlino×8
Invite
M. Carlino — researcher profile on SciRah
M. Del Vecchio×8
Invite
M. Del Vecchio — researcher profile on SciRah

×8

Invite

D. Schadendorf — researcher profile on SciRah

Invite

F. Spagnolo — researcher profile on SciRah

Invite

C. Robert — researcher profile on SciRah

Invite

G. Madonna — researcher profile on SciRah

Invite

R. Dummer — researcher profile on SciRah

Mario Mandalá×7

Invite

Mario Mandalá — researcher profile on SciRah

Invite

D. Mallardo — researcher profile on SciRah

Invite

G. Long — researcher profile on SciRah